Treatment of Sepsis with Talactoferrin

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$2,462,044.00
Award Year:
2008
Program:
SBIR
Phase:
Phase II
Contract:
4R44GM077816-02
Agency Tracking Number:
GM077816
Solicitation Year:
n/a
Solicitation Topic Code:
n/a
Solicitation Number:
n/a
Small Business Information
AGENNIX, INC.
AGENNIX, INC., 8 GREENWAY PLZ, STE 910, HOUSTON, TX, 77046
Hubzone Owned:
N
Socially and Economically Disadvantaged:
N
Woman Owned:
N
Duns:
808956700
Principal Investigator:
ATUL VARADHACHARY
(713) 552-1091
AVARADHACHARY@AGENNIX.COM
Business Contact:
() -
msmith@agennix.com
Research Institution:
n/a
Abstract
DESCRIPTION (provided by applicant): Severe sepsis is a major cause of morbidity and mortality throughout the world. It is the leading cause of death in non-coronary intensive care units (ICUs) in the United States, with more than 750,000 cases occurring e very year. This means that in the United States, more than 500 patients die from severe sepsis every day, with 28% to 50% of the patients succumbing to the disease process at an average cost of 22,000 per patient. Successful development of TLF-based thera py for sepsis would satisfy a significant unmet medical need. Agennix has now established a manufacture of a pharmaceutical-grade talactoferrin, it has demonstrated its safety in clinical studies for various indications, and is now interacting with the FDA to obtain a go-ahead to initiate clinical Phase 3 studies in cancer. The development of talactoferrin is therefore at a stage that a demonstration of its clinical efficacy in sepsis would put the generation of a product to treat sepsis on a relatively eas y and straightforward path.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government